Maxima and minima

Paramount Global Announces the Pricing Terms of its Maximum Tender Offers for Certain Outstanding Debt Securities

Retrieved on: 
Friday, November 17, 2023
Maxima and minima, Wells Fargo, Telephone, LM, Debt-to-GDP ratio, SMBC Nikko Securities, United States Treasury security, Treasury, Trustee, Bloomberg, RBC Capital Markets, Asset, Holder Formation, UST, Tender, Security (finance), Cryptocurrency, Paramount

Per $1,000 principal amount of Maximum Offer Securities validly tendered on or prior to the Early Tender Deadline (as defined below) and accepted for purchase.

Key Points: 
  • Per $1,000 principal amount of Maximum Offer Securities validly tendered on or prior to the Early Tender Deadline (as defined below) and accepted for purchase.
  • Paramount reserves the absolute right, subject to applicable law, to: (i) waive any and all conditions applicable to the Maximum Offer; (ii) extend or terminate the Maximum Offer; (iii) increase or decrease the Maximum Offer Amount without extending the Early Tender Deadline or the Maximum Offer Withdrawal Deadline; or (iv) otherwise amend the Maximum Offer in any respect.
  • The solicitation of offers to sell the Maximum Offer Securities is only being made pursuant to the terms of the Offer to Purchase.
  • None of Paramount, the Dealer Managers, the Tender Agent, the trustees with respect to the Maximum Offer Securities or any of their respective affiliates is making any recommendation as to whether Holders should tender their Maximum Offer Securities in connection with the Maximum Offer.

Paramount Global Announces Early Tender Results of its Maximum Tender Offers for Certain Outstanding Debt Securities

Retrieved on: 
Friday, November 17, 2023
Maxima and minima, Wells Fargo, Telephone, LM, Debt-to-GDP ratio, SMBC Nikko Securities, Trustee, RBC Capital Markets, Asset, Holder Formation, Tender, Security (finance), Life insurance, Cryptocurrency, Paramount

As of 5:00 p.m., New York City time, on November 16, 2023 (the "Maximum Offer Withdrawal Deadline"), Maximum Offer Securities validly tendered in the Maximum Offer may no longer be withdrawn except in certain limited circumstances where additional withdrawal rights are required by law.

Key Points: 
  • As of 5:00 p.m., New York City time, on November 16, 2023 (the "Maximum Offer Withdrawal Deadline"), Maximum Offer Securities validly tendered in the Maximum Offer may no longer be withdrawn except in certain limited circumstances where additional withdrawal rights are required by law.
  • Although the Maximum Offer is scheduled to expire at 5:00 p.m., New York City time, on December 4, 2023 (such date and time, as may be extended or earlier terminated by Paramount), because the Maximum Offer was fully subscribed as of the Early Tender Deadline, Paramount does not expect to accept for purchase any Maximum Offer Securities tendered after the Early Tender Deadline.
  • Paramount reserves the absolute right, subject to applicable law, to: (i) waive any and all conditions applicable to the Maximum Offer; (ii) extend or terminate the Maximum Offer; (iii) increase or decrease the Maximum Offer Amount without extending the Early Tender Deadline or the Maximum Offer Withdrawal Deadline; or (iv) otherwise amend the Maximum Offer in any respect.
  • None of Paramount, the Dealer Managers, the Tender Agent, the trustees with respect to the Maximum Offer Securities or any of their respective affiliates is making any recommendation as to whether Holders should tender their Maximum Offer Securities in connection with the Maximum Offer.

Paramount Global Announces the Expiration and Results of its Any and All Tender Offers for Certain Outstanding Debt Securities

Retrieved on: 
Friday, November 10, 2023
Maxima and minima, Wells Fargo, Telephone, LM, Debt-to-GDP ratio, SMBC Nikko Securities, Trustee, RBC Capital Markets, Accrued interest, All, Asset, Interest, Tender, Life insurance, Paramount

Holders are urged to read the Offer to Purchase carefully before making any decision with respect to the Maximum Offers.

Key Points: 
  • Holders are urged to read the Offer to Purchase carefully before making any decision with respect to the Maximum Offers.
  • The information agent and tender agent for the Any and All Offers is Global Bondholder Services Corporation.
  • Copies of the Offer to Purchase and the Notice of Guaranteed Delivery may be accessed at the following link: https://www.gbsc-usa.com/paramount .
  • The solicitation of offers to sell the Any and All Securities is only being made pursuant to the terms of the Offer to Purchase.

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Retrieved on: 
Tuesday, November 7, 2023
MTD, University College London, US, Maxima and minima, Doctor of Philosophy, Index, Orphan, ClinicalTrials.gov, GI/GU, Clinical trial, Oncogene, University College London Hospitals NHS Foundation Trust, Cancer, Pancreatic cancer, TD2, Safety, Therapy, Patient, Oncology, Pharmaceutical industry, Q4

It was discovered by Dr. Stephen Neidle’s team at the University College London and exclusively licensed by Qualigen in January 2021.

Key Points: 
  • It was discovered by Dr. Stephen Neidle’s team at the University College London and exclusively licensed by Qualigen in January 2021.
  • Qualigen received Orphan Drug Designation for the intended treatment of pancreatic cancer in January and clearance from the US FDA to initiate a Phase 1 clinical trial in July of this year.
  • Qualigen anticipates providing an update on safety and preliminary efficacy of the Phase 1a study in the first half of 2024.
  • For more information on QN-302 or the Phase 1a clinical trial, please visit our QN-302 clinical trial website on ClinicalTrials.gov.

Agrify Announces Transfer of its Existing Credit Facility and Expected New Equity Investment

Retrieved on: 
Monday, October 30, 2023
Cannabis, Sale, Injection, Senior, Common stock, Maxima and minima, Security (finance)

Raymond Chang, the Chief Executive Officer of the Company, is one of the principals of the New Lender.

Key Points: 
  • Raymond Chang, the Chief Executive Officer of the Company, is one of the principals of the New Lender.
  • “In 2023, we made tremendous efforts to reduce our operating loss and cash burn and have also worked to settle trade payables and reduce and restructure our liabilities,” said Mr. Chang.
  • On the extraction side of the business, our comprehensive solution offerings and new products continue to gain interest both domestically and internationally.
  • This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any future offering.

Paramount Global Announces Cash Tender Offers for Up to $1 Billion Combined Aggregate Purchase Price of Certain Outstanding Debt Securities

Retrieved on: 
Thursday, November 2, 2023
Treasury, Trustee, Asset, All, Bloomberg, Debt-to-GDP ratio, SMBC Nikko Securities, LM, Telephone, TD, UST, Security (finance), Tender, Interest, RBC Capital Markets, Maxima and minima, United States Treasury security, Date, Wells Fargo, Table, Accrued interest, Cryptocurrency, Life insurance, Auction, Paramount, Offers

Per $1,000 principal amount of Maximum Offer Securities validly tendered on or prior to the Early Tender Deadline (as defined below) and accepted for purchase.

Key Points: 
  • Per $1,000 principal amount of Maximum Offer Securities validly tendered on or prior to the Early Tender Deadline (as defined below) and accepted for purchase.
  • Holders of Maximum Offer Securities who validly tender their Maximum Offer Securities following the Early Tender Deadline and on or prior to the Maximum Offer Expiration Date will only receive the applicable Maximum Offer Consideration (as defined below) per $1,000 principal amount of any such Maximum Offer Securities validly tendered by such Holders that are accepted for purchase.
  • If the Maximum Offer is fully subscribed as of the Early Tender Deadline, Holders who validly tender Maximum Offer Securities following the Early Tender Deadline but on or prior to the Maximum Offer Expiration Date will not have any of their Maximum Offer Securities accepted for purchase regardless of their Acceptance Priority Level.
  • The solicitation of offers to sell the Securities is only being made pursuant to the terms of the Offer to Purchase.

Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon

Retrieved on: 
Monday, October 16, 2023
Annual report, TSX, Credit, Rolling Stone's 500 Greatest Albums of All Time, Warrant, Maxima and minima, EBITDA, Marathon Asset Management, Documentation, Exercise, Marathon, Credit agreements in South Africa, News, Security (finance)

MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has finalized all documentation giving effect to the amendments to certain of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time (the “Credit Agreement”), with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, “Marathon”).

Key Points: 
  • - Revised the Minimum Liquidity Covenant for All Times Following October 31, 2023 to be Between US$15 Million and US$20 Million
    This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021.
  • MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has finalized all documentation giving effect to the amendments to certain of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time (the “Credit Agreement”), with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, “Marathon”).
  • Following the share consolidation completed on July 31, 2023, the exercise of four Warrants and the payment of US$2.30 are required to subscribe to one common share of Theratechnologies, for up to a maximum issuance of 1,250,000 common shares.
  • The Warrants can be exercised until February 27, 2030.

Safeguard Scientifics’ Board of Directors Approves Plan to Voluntarily Terminate Registration of Its Common Stock with the SEC and Voluntarily Delist from Nasdaq

Retrieved on: 
Thursday, October 5, 2023
Schedule, Pete Musser, Special, Minimum number of individuals, Reverse stock split, Maxima and minima, Safeguard, Cash out refinancing, SFE, Cryptocurrency, Security (finance)

In order to deregister its shares of common stock, the Company must reduce its number of shareholders of record to below 300.

Key Points: 
  • In order to deregister its shares of common stock, the Company must reduce its number of shareholders of record to below 300.
  • Upon the forward stock split, the shares of common stock (including any fraction of a share of common stock) held by such Continuing Shareholders after the reverse stock split will be reclassified into the same number of shares of common stock as such Continuing Shareholders held immediately prior to the effective time.
  • As a result of the forward stock split, the total number of shares of common stock held by a Continuing Shareholder would not change due to the stock splits.
  • If the Stock Split Proposals are approved by shareholders at the Special Meeting and the Board decides to proceed with the going private transaction, the Company will take steps to terminate the registration of its common stock with the SEC and delist its common stock from trading on Nasdaq.

OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors

Retrieved on: 
Monday, October 16, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Ligand, Tumor microenvironment, Mnemos EP, Hepatocellular carcinoma, AACR, PD-L1, Communication, MTD, Preventive healthcare, Index, OSE, PD-L2, ISIN, Maxima and minima, Conference, Patient, Pharmaceutical industry

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).
  • Silvia Comis, Head of Clinical Development and Regulatory Affairs of OSE Immunotherapeutics, comments: “These first efficacy and safety positive results from clinical Phase 1/2 assessing the therapeutic potential of our proprietary anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors are very promising.
  • These results encourage further clinical development of OSE-279 in the future as a monotherapy treatment in pre-identified cancer niche indications, with still high unmet medical needs.
  • This product will also be available for combination with other OSE drug candidates or with external assets opening new potential partnerships.”
    The communication reported on the first positive results from the Phase 1/2 clinical trial evaluating OSE-279 monotherapy in patients with advanced solid tumors, with no therapeutic option available.

Kinetech Launches Mendix Enablement Practice to Accelerate Client Adoption of Low-code

Retrieved on: 
Tuesday, October 3, 2023
Sneakers, Culture, Process, Curriculum, Attention, Element, Improper integral, Start, Organization, Structure, Partner, Engineering, Center of excellence, MVP, COE, Quality control, Digital, Maxima and minima, Scrum, Software, Construction, Management, Asset management, Sales, Risk management, Tutoring, Medical device, Architecture

SAN ANTONIO, Oct. 3, 2023 /PRNewswire-PRWeb/ -- Kinetech is proud to announce the launch of our Mendix Client Enablement Practice. Our Practice is led by dual Mendix certified expert engineers and T3 (Train-The-Trainer) trainers. These unique qualifications bring decades of Mendix engineering expertise with educational excellence, further positioning Kinetech as a leading Mendix partner in the United States.

Key Points: 
  • Kinetech Launches Mendix Enablement Practice: Empowering Organizations with Expertise and a Proven Digital Execution Strategy
    SAN ANTONIO, Oct. 3, 2023 /PRNewswire-PRWeb/ -- Kinetech is proud to announce the launch of our Mendix Client Enablement Practice.
  • These unique qualifications bring decades of Mendix engineering expertise with educational excellence, further positioning Kinetech as a leading Mendix partner in the United States.
  • Most importantly, Kinetech will teach your team how to build custom solutions with Mendix, and thus lead the effort to establish your internal Mendix practice.
  • Expert Led Enablement Practice: When selecting an enablement partner it's important to verify that they offer actual enablement services.